Arbitrage SBIR Phase II Bridge via Convertible Note Financing
- Organization
- National Science Foundation (NSF)
- Sector
- Early-stage biotech companies with SBIR Phase I awards
- Location
- United States
Source Reference
Executive Context
NSF awarded $305K SBIR Phase I funding to ENDURE BIOTHERAPEUTICS for a precision microbiome therapeutic platform targeting PKU, creating a structural 6-month funding cliff and commercial execution gap despite government validation of the technology.
Catalyst / Timing
Structural 6-month funding cliff between SBIR Phase I ($305K) and Phase II ($1M+) creates immediate cash flow crisis for ENDURE BIOTHERAPEUTICS despite government validation of their technology platform, forcing them to accept unfavorable bridge terms or risk losing momentum.
Projected Yield
Capital Estimate
$100K bridge note with 25% discount to Phase II implied valuation of $5M = $125K conversion value. With 10% simple interest over 6 months = $5K interest. Warrant coverage (20% of $100K = $20K warrant at same terms) adds additional $5K upside. Total potential: $135-150K return on $100K in 6-9 months (35-50% IRR).
Resource Capture
Proprietary database of SBIR award timelines and company financials for future targeting. Legal templates for milestone-triggered convertible notes specifically designed for government-funded biotechs. Network access to Gilbert Keller's UCSD and biotech investor connections.
Influence Capture
Position as the go-to SBIR bridge financing specialist for UCSD biotech spinouts. First successful deal creates reference case for approaching the ~50 other UCSD-affiliated companies with active SBIR awards. Establishes authority in the niche intersection of government funding and early-stage biotech.
Sovereignty Yield
Establishment of a novel financial instrument structure (milestone-triggered convertible notes for SBIR companies) that could become standard practice in the niche. First-mover advantage in systematizing the arbitrage of government funding gaps.
Time to First Yield
45-60 days to signed note agreement; 6-9 months to conversion and realized return upon SBIR Phase II award (expected Q4 2024 based on NSF timelines).
Scaling Path
Once the instrument structure and outreach methodology are proven with ENDURE, the operation scales through three channels:
-
Horizontal expansion to other UCSD SBIR awardees (8-12 new targets immediately available),
-
Vertical expansion to other research universities with strong SBIR pipelines (Stanford, MIT, UW),
-
Productization of the white paper and term sheet templates as a paid consultancy service for investors seeking exposure to government-funded biotech.
Structural Friction
- Likely Point of Failure
ENDURE's scientific founders reject financial engineering due to unfamiliarity with convertible instruments, preferring to bootstrap with personal funds or seek non-dilutive grants despite the cash flow crisis. Academic founders often prioritize control over speed, creating a cultural mismatch with venture-style financing.
- Mitigation Tactic
Structure the outreach as educational content first: create a 2-page white paper titled 'Navigating the SBIR Phase I-II Funding Cliff: Convertible Note Strategies for Biotech Startups' that explains the mechanics in simple terms with case studies. Lead with this educational asset rather than the term sheet, positioning as a consultant first, financier second. Simultaneously, identify and warm-introduce through their existing investor network (if any) to build credibility through association.
- Go / No-Go Trigger
Confirmation that ENDURE BIOTHERAPEUTICS, INC. has not already secured bridge financing through existing investors or alternative lenders, verified through absence of new Form D filings in the last 90 days and no public announcements of bridge rounds.
Required Capabilities
Vector: Venture Finance
Primary executor: Phase 1: Forensic Financial Reconnaissance & Pressure Point Mapping: Conduct forensic financial and corporate reconnaiss
Vector: Biotech Regulatory
Supporting vector for: Arbitrage SBIR Phase II Bridge via Convertible Note Financing
Vector: Legal Contracting
Supporting vector for: Arbitrage SBIR Phase II Bridge via Convertible Note Financing
Execution Protocol
Execution Protocol Locked
A one-time payment of $1799 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.